Lowering Blood Pressure in Primary Care in Vienna

Hypertension Clinical Trial

— Low BP Vienna  

Official title:

Lowering Blood Pressure in Primary Care in Vienna

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02377661
• Other study ID #: V1-19012014
• Status: Completed
• Phase: Phase 4
• First received: February 16, 2015
• Last updated: August 15, 2017
• Start date: March 2015
• Est. completion date: May 30, 2017

Study information

• Verified date: August 2017
• Source: Wilhelminenspital Vienna
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this prospective, randomised, open-label, multicentre clinical trial is to enhance blood pressure control in primary care by introducing a standardised and simplified titration regime with single pill combinations (SPC), comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.

Description:

Rationale Hypertension is the single largest contributor to mortality worldwide, accounting for 13% of deaths globally. Approximately 30% of the adult population suffer from hypertension and of those diagnosed and treated, only 30-50% have adequately controlled blood pressure. At present, the importance of hypertension as fundamental risk factors is inadequately addressed among many patients and physicians.

Design The aim of this prospective, randomised, open-label, multicentre clinical trial is to enhance blood pressure control in primary care by introducing a standardised and simplified titration regime with single pill combinations (SPC), comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.

The trial will randomise 42 family doctors or resident specialists for internal medicine (enrolling 840 patients with treated or untreated hypertension) to either experimental care or standard care for hypertension, latter according to the 2013 European Society of Cardiology Guidelines for the Management of Arterial Hypertension.

Practitioners randomised to experimental care will up-titrate antihypertensive therapy with SPCs in 4-week intervals if the target blood pressure of < 140/90 mmHg is not reached at the respective follow-up (Figure 1).

Study Outcomes The primary efficacy endpoint will be the proportion of patients achieving the target office blood pressure after 6 months of follow-up. The main secondary endpoint will be the improvement of 24h ambulatory blood pressure (ABPM) profile, measured at inclusion and after 6 months of follow-up.

Safety assessments include the evaluation of treatment emergent adverse events, particularly hospitalisation, worsening of renal function, peripheral oedema and hypotension.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 229
• Est. completion date: May 30, 2017
• Est. primary completion date: May 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Written informed consent

• office blood pressure = 140/90 mmHg

• ACE inhibitor intolerance (experimental arm)

Exclusion Criteria:

• Malignant disease with life expectancy < 6 months

• Women of childbearing potential (ICH definition) or breastfeeding

• Contraindications or allergies against olmesartan, amlodipine or hydrochlorothiazide (experimental arm)

• Chronic kidney disease grade IV or V (eGFR < 30 ml/min)

• Recent myocardial infarction or stroke within the preceding 3 months

• Participation in another clinical trial

Related Conditions & MeSH terms

• Hypertension

Intervention

Drug:
• Olmesartan medoxomil, amlodipine, hydrochlorothiazide
Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of < 140/90 mmHg is not reached at the respective follow-up

Locations

Country	Name	City	State
Austria	GP practices	Vienna

Sponsors (3)

Lead Sponsor	Collaborator
Wilhelminenspital Vienna	Association for the Promotion of Research in Atherosclerosis, Thrombosis and Vascular Biology, Ludwig Boltzmann Foundation for Cardiovascular Research

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Achievement of the target office blood pressure (< 140/90 mmHg)	Proportion of patients achieving the target office blood pressure of 140/90 mmHg	6 months
Primary	Achievement of the target systolic office blood pressure (< 140 mmHg)	Proportion of patients achieving the target systolic office blood pressure of 140 mmHg	6 months
Primary	Achievement of the target diastolic office blood pressure (< 90 mmHg)	Proportion of patients achieving the target diastolic office blood pressure of 90 mmHg	6 months
Secondary	Achievement of the target average 24h systolic ambulatory blood pressure (< 130 mmHg)	Average 24h systolic ambulatory blood pressure reading below 130 mmHg	6 months
Secondary	Achievement of the target average 24h diastolic ambulatory blood pressure (< 80 mmHg)	Average 24h diastolic ambulatory blood pressure reading below 80 mmHg	6 months
Secondary	Achievement of the target average daytime systolic ambulatory blood pressure (< 135 mmHg)	Average daytime systolic ambulatory blood pressure reading below 135 mmHg	6 months
Secondary	Achievement of the target average nighttime systolic ambulatory blood pressure (< 120 mmHg)	Average nighttime systolic ambulatory blood pressure reading below 120 mmHg	6 months
Secondary	Achievement of the target average daytime diastolic ambulatory blood pressure (< 85 mmHg)	Average daytime diastolic ambulatory blood pressure reading below 85 mmHg	6 months
Secondary	Achievement of the target average nighttime diastolic ambulatory blood pressure (< 70 mmHg)	Average nighttime diastolic ambulatory blood pressure reading below 70 mmHg	6 months